Welcome to Idorsia

Idorsia announced financial results for the first nine months of 2019

Our key assets have
the potential to
transform treatment in
the target indications...

Read about how our IT department
achieved operational independence
ahead of schedule...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

22 Oct 2019	Idorsia announces financial results for the first nine months of 2019
02 Oct 2019	Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019
11 Sep 2019	Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis

Event	When
Full-Year 2019 Financial Results reporting*	February 6, 2020
First Quarter 2020 Financial Results reporting*	April 23, 2020
Annual General Meeting of Shareholders	May 13, 2020
Half-Year 2020 Financial Results reporting*	July 23, 2020

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 13:22:09 CET

22.68 CHF

-0.40 (-1.73 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland